BeOne Medicines Ltd. (ONC)
NASDAQ: ONC · Real-Time Price · USD
264.42
-5.21 (-1.93%)
Jun 16, 2025, 4:00 PM - Market closed
BeOne Medicines Revenue
BeOne Medicines had revenue of 8.05B CNY in the quarter ending March 31, 2025, with 48.28% growth. This brings the company's revenue in the last twelve months to 30.34B, up 52.09% year-over-year. In the year 2024, BeOne Medicines had annual revenue of 27.81B with 59.51% growth.
Revenue (ttm)
30.34B CNY
Revenue Growth
+52.09%
P/S Ratio
6.71
Revenue / Employee
2,757,959 CNY
Employees
11,000
Market Cap
33.69B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 27.81B | 10.38B | 59.51% |
Dec 31, 2023 | 17.43B | 7.67B | 78.53% |
Dec 31, 2022 | 9.77B | 2.29B | 30.69% |
Dec 31, 2021 | 7.47B | 5.46B | 270.56% |
Dec 31, 2020 | 2.02B | -965.08M | -32.37% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ONC News
- 19 hours ago - BeOne Medicines: Brukinsa Momentum And Pipeline Catalysts Justify Its Premium - Seeking Alpha
- 5 days ago - BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025 - Business Wire
- 5 days ago - U.S. FDA Approves Tablet Formulation of BeOne's BRUKINSA® for All Approved Indications - Business Wire
- 6 days ago - BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025 - Business Wire
- 12 days ago - BeOne Medicines: Competitive Advantage Of Zanubrutinib In The CLL Field - Seeking Alpha
- 15 days ago - BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025 - Business Wire
- 16 days ago - BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA's Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025 - Business Wire
- 20 days ago - BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology - Business Wire